Triple Agonist Mechanism: How Retatrutide Targets GLP-1, GIP & Glucagon

The Three Receptors: What Each One Does

Receptor	Primary Hormone	Key Effects When Activated	Net Impact on Obesity	Retatrutide Activity
GLP-1R (GLP-1 receptor)	Glucagon-like peptide-1	Suppresses appetite; slows gastric emptying; stimulates insulin secretion; reduces glucagon from pancreas	Eat less, feel full longer, lower blood glucose	Agonist ✓
GIPR (GIP receptor)	Glucose-dependent insulinotropic polypeptide	Enhances GLP-1-mediated insulin secretion; may reduce GI side effects of GLP-1R agonism; promotes fat utilization; reduces inflammation	Synergizes with GLP-1 to amplify weight loss; may improve tolerability	Agonist ✓
GCGR (Glucagon receptor)	Glucagon	Increases energy expenditure; promotes lipolysis (fat breakdown) in adipose tissue; promotes fatty acid oxidation in liver; stimulates thermogenesis	Burn more, reduce liver fat — the critical differentiator vs dual agonists	Agonist ✓

Single vs Dual vs Triple: The Efficacy Ladder

Single Agonist

Semaglutide (Wegovy, Ozempic) — GLP-1R only

14.9%

mean weight loss (STEP-1, 68 wks)

Activates only GLP-1 receptors. Appetite suppression is the primary mechanism. No GIP or glucagon receptor engagement. Highly effective but represents the first generation of GLP-1 therapeutics.

Dual Agonist

Tirzepatide (Zepbound, Mounjaro) — GIP/GLP-1

22.5%

mean weight loss (SURMOUNT-1, 72 wks)

Co-activates GIP and GLP-1 receptors. Adding GIPR agonism to GLP-1R agonism produces a ~7.6 percentage-point jump in weight loss over semaglutide. The synergy appears to reduce GI side effects while amplifying efficacy — the GIP receptor paradox (agonism reduces nausea rather than increasing it).

Triple Agonist — Investigational

Retatrutide (LY3437943) — GLP-1/GIP/Glucagon

28.7%

mean weight loss (TRIUMPH-4, 68 wks, 12 mg)

Adds glucagon receptor agonism on top of GIP/GLP-1 co-activation. The glucagon component drives a further ~6 percentage-point jump in weight loss vs tirzepatide. Not yet FDA-approved — this is the investigational Phase 3 signal that has generated the most interest in obesity pharmacotherapy.

⚠ TRIUMPH-4 data is top-line only. Peer-reviewed publication and full Phase 3 data pending. Not a head-to-head comparison to tirzepatide.

Why Glucagon Receptor Agonism Drives Extra Weight Loss

Glucagon is typically thought of as a counter-regulatory hormone that raises blood glucose — the opposite of insulin. So how can activating glucagon receptors help with weight loss?

The key is context. In retatrutide, glucagon receptor agonism occurs simultaneously with GLP-1 receptor agonism. GLP-1R activation suppresses endogenous glucagon secretion from the alpha cells of the pancreas and potently stimulates insulin release. This negates the hyperglycemic (blood-sugar-raising) risk of glucagon receptor activation.

What remains is the glucagon receptor's metabolic and thermogenic signaling in non-pancreatic tissues:

1. Increased Energy Expenditure (Thermogenesis)

Glucagon receptor signaling in adipose tissue and skeletal muscle promotes thermogenesis — the generation of heat from fuel. In rodent models and in Phase 2 human data, glucagon receptor agonists have been shown to increase resting energy expenditure by approximately 4–8%. Over 68 weeks, this "burn more" signal stacks on top of the "eat less" signal from GLP-1R agonism to produce cumulative weight loss that single-mechanism approaches cannot match.

2. Hepatic Fat Reduction

Glucagon receptor activation in the liver stimulates fatty acid oxidation and suppresses lipogenesis (fat synthesis). Phase 2 retatrutide data showed substantial reductions in hepatic fat fraction — a meaningful clinical benefit given that non-alcoholic fatty liver disease (now termed MASH/NAFLD) affects a large proportion of people with obesity. This hepatic mechanism is underappreciated but may drive some of the incremental efficacy over tirzepatide.

3. Lipolysis in Adipose Tissue

Glucagon receptor activation in white adipose tissue promotes the breakdown of stored triglycerides into free fatty acids (lipolysis). Combined with the reduced caloric intake from GLP-1R-mediated appetite suppression, the body mobilizes and oxidizes fat at a higher rate. This "metabolic double action" — eat less AND burn more — may explain the magnitude of weight loss seen in TRIUMPH-4.

Why Doesn't Triple Agonism Simply Triple the Side Effects?

A reasonable concern. In practice, the receptor interactions appear to be partially compensatory. The GIP receptor component appears to attenuate some of the GI side effects of GLP-1R agonism (this is well-documented with tirzepatide vs semaglutide). The glucagon receptor component adds new signals — most notably, the dysesthesia (abnormal skin sensation) observed in 8.8–20.9% of TRIUMPH-4 participants — but the existing GI side effect profile at 12 mg in TRIUMPH-4 (nausea 43%, vomiting 21%) is within the range seen for semaglutide 2.4 mg (nausea ~44%, vomiting ~24%).

The net tolerability profile is complex: superior weight loss efficacy, comparable GI side effects, and a new class-specific signal (dysesthesia) that requires further characterization. This is why the full Phase 3 program is needed before any regulatory decision.

Comparison of Receptor Agonism Profiles

Drug	GLP-1R	GIPR	GCGR	Approval Status	Peak Weight Loss
Semaglutide (Wegovy)	✓	—	—	FDA-approved (obesity)	14.9% (STEP-1)
Tirzepatide (Zepbound)	✓	✓	—	FDA-approved (obesity & T2D)	22.5% (SURMOUNT-1)
Retatrutide ⚠	✓	✓	✓	Investigational — Phase 3	28.7% (TRIUMPH-4)

⚠ Retatrutide is NOT FDA-approved. TRIUMPH-4 is top-line data from a single Phase 3 trial in obesity + knee OA. Not a direct head-to-head comparison.

Does Triple Agonism Affect Lean Muscle Mass?

A key concern with all obesity drugs is the ratio of fat mass to lean mass lost. If a drug causes significant lean mass loss, metabolic consequences can follow (reduced resting metabolic rate, weakness, etc.). Preliminary Phase 2 retatrutide data suggested a favorable fat/lean mass ratio — but the Phase 3 program will provide more definitive body composition data from DEXA scans.

This question is especially interesting for retatrutide given the glucagon receptor component: glucagon promotes lipolysis (fat breakdown) specifically, which could theoretically lead to a higher proportion of fat loss relative to lean mass. Confirmation awaits Phase 3 publication.

Sources

Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
BioSpace — TRIUMPH-4 Phase 3 readout (December 2025): Lilly's retatrutide scores triple trial triumph
Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)." NEJM 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

Frequently Asked Questions

Why does adding glucagon agonism produce more weight loss?

Glucagon receptor activation increases resting energy expenditure by an estimated 5–10%, promotes fat oxidation, and reduces hepatic fat. GLP-1 alone affects intake; adding glucagon affects output. The combination changes both sides of the energy balance equation.

Doesn't glucagon raise blood sugar? How can a glucagon agonist help diabetes?

In isolation, yes — glucagon promotes hepatic glucose output. In retatrutide, the GLP-1 component's glucose-dependent insulinotropic effect more than offsets glucagon's hyperglycemic effect, and the resulting net effect on glucose is favorable in most patients. At very high doses, fasting glucose can rise modestly.

Is GIP activation necessary, or is it just for nausea reduction?

GIP activation appears to do more than just reduce nausea. Tirzepatide (GIP + GLP-1, no glucagon) produces ~21% weight loss vs ~15% for semaglutide (GLP-1 only). The GIP contribution appears to be both tolerability-improving and modestly weight-loss-augmenting.

Are there other triple agonists in development?

Yes. Mazdutide (GLP-1 + glucagon), survodutide (GLP-1 + glucagon), and several preclinical candidates are exploring combinations including all three pathways. Retatrutide is currently the most clinically advanced triple agonist.

Could a quadruple agonist be even more effective?

Researchers are exploring this — adding amylin, PYY, or other gut hormones to GLP-1/GIP/glucagon backbones. Whether more receptor targets translates to more weight loss without additional side effects is an empirical question; receptor crosstalk and tolerability ceilings matter.